40
Participants
Start Date
October 1, 2019
Primary Completion Date
June 30, 2025
Study Completion Date
October 30, 2025
Psychosis and cognitive assessments
Administration of MINI, PANSS and Quality of Living scales
Physical and neuro-cognitive evaluations
Physical, neurological and cognitive evaluations.
Safety labs and electrocardiogram
Metabolic panel, CBC and differential, urinalysis, ECG, recreational drugs. CD19+ B-cell count.
Ocrelizumab infusion
Two IV infusions of 300 mg of ocrelizumab 2 weeks apart
RECRUITING
Houston Methodist Research Institute, Houston
Collaborators (1)
Genentech, Inc.
INDUSTRY
The Methodist Hospital Research Institute
OTHER